Literature DB >> 16387410

Lich-Gregoir reimplantation causes less discomfort than Politano-Leadbetter technique: Results of a prospective, randomized, pain scale-oriented study in a pediatric population.

C Schwentner1, J Oswald, A Lunacek, M Deibl, I Koerner, G Bartsch, Christian Radmayr.   

Abstract

OBJECTIVE: There is a consensus that transvesical reimplantation is more appropriate in cases of bilateral vesicoureteral reflex (VUR). In contrast to that it is not yet clear which approach should be used in unilateral VUR. This prospective, randomized trial compared the benefits and drawbacks of the intravesical and extravesical techniques in terms of operative comorbidity.
METHODS: Forty-four children (29 girls, 15 boys, mean age, 67.23 mo) with unilateral VUR were assigned to two groups: 22 patients underwent Lich-Gregoir reimplantation and 22 underwent the intravesical Politano-Leadbetter technique. Follow-up evaluation included renal ultrasonography and voiding cystourethrography (VCUG) 6 mo postoperatively. The groups were compared for operative time, duration of hematuria, upper tract dilation, discomfort and pain, analgesic requirements, voiding dysfunction, and reflux persistency.
RESULTS: No child had persistent VUR. Contralateral degrees II VUR was noted in five patients without significant difference regarding the treatment (p = 0.345). It was transient in all cases. Operative time was shorter using the extravesical technique (66.73 min versus 79.28 min; p < 0.0001). Gross hematuria occurred only after intravesical reimplantation lasting 4.19 d (p < 0.00001). The objective pain score was worse after intravesical surgery (p = 0.002). Analgesic requirements were higher after the Politano reimplantation (p = 0.039).
CONCLUSIONS: Both unilateral extravesical and intravesical reimplantation definitively correct VUR. The mean operative time was significantly shorter using the Lich-Gregoir technique, which underlines its simplicity; additionally, gross hematuria can be avoided. Postoperative pain and bladder spasms were reduced using the extravesical approach. Consequently, it represents an effective surgical technique to correct reflux while operative morbidity is low. Therefore it is the method of choice in cases of unilateral VUR requiring correction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16387410     DOI: 10.1016/j.eururo.2005.11.015

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  7 in total

1.  [Treatment of vesicoureteral reflux in childhood].

Authors:  I Körner; J Steffens
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

Review 2.  [Vesicoureteral reflux: diagnostics and therapy].

Authors:  W H Rösch; V Geyer
Journal:  Urologe A       Date:  2011-06       Impact factor: 0.639

Review 3.  WITHDRAWN: Diclofenac for acute pain in children.

Authors:  Joseph F Standing; Imogen Savage; Deborah Pritchard; Marina Waddington
Journal:  Cochrane Database Syst Rev       Date:  2015-07-02

4.  [Perioperative pain management in major reconstructive surgery in pediatric urology: a plea for continuous epidural anesthesia].

Authors:  P C Rubenwolf; B Koller; I Rübben; A-K Ebert; F Pohl; W H Rösch
Journal:  Urologe A       Date:  2011-05       Impact factor: 0.639

Review 5.  Therapy for vesicoureteral reflux: antibiotic prophylaxis, urotherapy, open surgery, endoscopic injection, or observation?

Authors:  Jack S Elder
Journal:  Curr Urol Rep       Date:  2008-03       Impact factor: 3.092

6.  Surgical Reimplantation for the Correction of Vesicoureteral Reflux following Failed Endoscopic Injection.

Authors:  Boris Chertin; Ksenia Prosolovich; Sagiv Aharon; Ofer Nativ; Sarel Halachmi
Journal:  Adv Urol       Date:  2011-01-09

7.  Unilateral extravesical ureteral reimplantation via inguinal incision for the correction of vesicoureteral reflux: a 10-year experience.

Authors:  Michael Yap; Unwanabong Nseyo; Hena Din; Madhu Alagiri
Journal:  Int Braz J Urol       Date:  2017 Sep-Oct       Impact factor: 1.541

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.